Caterpillar Gears Up as the Dow Jumps to Near-Record High

Shire Pharmaceuticals' stock roars higher as the company turns down AbbVie's buyout bid.

Jun 20, 2014 at 2:30PM
Daily Fool

The market is closing out the week on a high note, with the Dow Jones Industrial Average (DJINDICES:^DJI) up 26 points as of 2:35 p.m. EDT and still flirting with another record high. While the index has dropped a bit in afternoon trading, the majority of the index's member stocks remain in the green. Caterpillar (NYSE:CAT) is up 1.7% to become the big winner on the Dow so far today, even on lackluster sales news. Meanwhile, Shire Pharmaceuticals (NASDAQ:SHPG) shares have gained nearly 17%. Let's catch up on what you need to know.

Caterpillar sales under fire

Cat Thing

Source: Caterpillar Media Gallery.

Caterpillar's stock leaped more than 19% since 2014 kicked off, but the company is still working on how to turn around the ongoing sales slide of its heavy machinery. The industrial giant this week reported that its Asia-Pacific dealer sales declined by 30% in the three months ended in May, worsening a 25% slump in such sales from the three-month period through April. Overall dealer sales declined by 12% in the three months that ended in May, with even some of the company's best-performing regions feeling the hit from the mining sector's slump.

Mining has struggled to recover in the years since the recession ended. Caterpillar's resource industry group, which produces machinery for the mining sector, saw dealer sales slump by 69% in its Asia-Pacific business and by 47% in its Africa, Middle East, and European group. Only North America showed any sign of success over the latest three-month reporting period, as the resource industry saw a 7% increase in dealer sales. While the U.S.' ongoing housing rise and steady economic growth bode well for Caterpillar -- particularly as the company's largest geographic segment -- the company will need to ratchet up international revenue in the near future. Sales from outside of North America made up more than 60% of the company's overall revenue last year, and the Asia-Pacific region in particular saw a 28% overall revenue decline in 2013.

In the health-care sector, Shire's stock bloomed today after the company turned down the latest buyout bid in what has turned out to be a year dominated by merger and acquisition talk in the pharmaceutical industry. Big Pharma's AbbVie (NYSE:ABBV) offered more than $46 billion to acquire Shire, hoping to follow in the footsteps of Medtronic's recent big buyout of Covidien by snapping up a foreign competitor and incorporating abroad. AbbVie can maintain its pursuit of Shire until mid-July under U.K. rules before having to wait six months to try again, so this acquisition hunt may continue if AbbVie is gunning to lower its tax bill.

Shire, however, has made it clear that it's not biting. In a note saying that AbbVie's latest offer significantly undervalues the drugmaker, the company claimed that it can double its annual product revenue to $10 billion by 2020. Analysts have noted that AbbVie, which has made its name selling the world's top-selling drug, immunology therapy Humira, has little synergies with Shire in terms of drug specializations, so likely benefits would stem primarily from the tax savings of incorporating in a foreign nation, along with cost-cutting moves.

Will this stock be your next multibagger?
Give us five minutes and we'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks one stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.

Dan Carroll has no position in any stocks mentioned. The Motley Fool recommends Covidien. The Motley Fool owns shares of Medtronic. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers